As per DelveInsight estimation, the future of haemophilia treatment is continuing to trend toward extended half-life therapies and more novel approaches, including siRNA, bi-specific antibodies and gene therapy. If these therapies are successfully commercialized, they can transform the current standard of care for Hemophilia A patients.
DelveInsight’s “Hemophilia A Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hemophilia A market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Hemophilia A market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hemophilia A: An Overview
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. About 30% of severe Hemophilia A patients develop neutralizing anti-FVIII alloantibodies (inhibitors), which render the FVIII replacement ineffective. The standard of care therapy for patients with inhibitors is to induce immune tolerance with high-dose, high-frequency FVIII and treatment with bypassing agents (e.g. recombinant activated factor VII such as NovoSeven, FEIBA).
The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A.
Hemophilia A Market – Key Highlights
The total Hemophilia A Market Size in the 7MM was USD 8,510 million in 2021 and is projected to grow during the forecast period (2022-2032). The highest market size of Hemophilia A is from the United States in 2021.
The total prevalent population of Hemophilia A in the 7MM were 45,100+ in 2021 and is projected to increase during the forecast period.
The total prevalent population of Hemophilia A in the United States were 14,100+ in 2021.
Among the EU5 countries, France has the maximum revenue share, followed by the United Kingdom in 2021, while Spain has the lowest market share.
As per DelveInsight, the Hemophilia A Market Size in Japan was USD 956 million in 2021.
Some of the leading pharma giants in the Hemophilia A Market include BioMarin Pharmaceutical, Roche (Spark Therapeutics), ApcinteX, Novo Nordisk, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx Pharmaceutical, and others.
Hemophilia A Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hemophilia A market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Hemophilia A market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hemophilia A Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Hemophilia A Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia A market or expected to get launched during the study period. The analysis covers the Hemophilia A market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hemophilia A Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Hemophilia A Market Will Evolve by 2032:
https://www.delveinsight.com/sample-request/hemophilia-a2030-market
The Hemophilia A market size is expected to increase in the coming year owing to the rise in the prevalent population of Hemophilia A, the expected entry of premium price assets such as gene therapy, siRNA, and bispecific antibodies, and the expected readily uptake of recently approved therapies.
Some of the key companies in the Hemophilia A market include:
Biomarin Pharmaceutical
Novo Nordisk
Sanofi
Pfizer
Catalyst Biosciences
OPKO Biologics
Spark Therapeutics
Sangamo therapeutics
Bayer
Ultragenyx Pharmaceutical
And many others
Hemophilia A Therapies covered in the report include:
Fitusiran
Concizumab (NN7415)
Marstacimab (PF-06741086)
Marzeptacog alfa
Valoctocogene Roxaparvovec
BIVV001
SPK-8011
SB-525
And many others.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hemophilia A Competitive Intelligence Analysis
4. Hemophilia A Market Overview at a Glance
5. Hemophilia A Disease Background and Overview
6. Hemophilia A Patient Journey
7. Hemophilia A Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Hemophilia A Treatment Algorithm, Current Treatment, and Medical Practices
9. Hemophilia A Unmet Needs
10. Key Endpoints of Hemophilia A Treatment
11. Hemophilia A Marketed Products
12. Hemophilia A Emerging Drugs and Latest Therapeutic Advances
13. Hemophilia A Seven Major Market Analysis
14. Attribute Analysis
15. Hemophilia A Market Outlook (In US, EU5, and Japan)
16. Hemophilia A Access and Reimbursement Overview
17. KOL Views on the Hemophilia A Market
18. Hemophilia A Market Drivers
19. Hemophilia A Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
Other Trending Healthcare Reports By DelveInsight
Hemophilia A Pipeline Insights
“Hemophilia A – Pipeline Insights, 2022,” report provides comprehensive insights about 40+ companies and 40+ drugs in the Hemophilia A pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
